We have expanded our IP portfolio for our key technology.
Whilst our original patent application to deliver seRNA via plasmid DNA is currently in its nationalization phase, with Japan already granting the patent and other countries expecting to do so shortly, we have last week submitted a new patent application to protect the delivery of improved seRNA as an RNA molecule.
Thus, this establishes seRNA as novel platform technology. It enables target cell selective RNA therapeutics in numerous indications and therapeutics areas and by selection of a delivery approach that is best suited for the indication we intend to target.